XZB-0004 + penpulimab

XZB-0004 + penpulimab is an experimental fixed combination of XZB-0004 and penpulimab, under clinical investigation for the treatment of advanced solid tumors including non-small cell lung cancer (NSCLC)[2]. Penpulimab is a programmed death receptor-1 (PD-1)-blocking humanized monoclonal antibody immunotherapy. The mechanism of XZB-0004 is not fully defined in publicly available sources, but the drug is being evaluated for safety and efficacy in advanced cancer patients alongside penpulimab[2]. Penpulimab inhibits the interaction of PD-1 with its ligands, thereby enhancing the immune system's ability to recognize and destroy cancer cells. Penpulimab has established regulatory approval for the treatment of nasopharyngeal carcinoma (NPC) and other cancer indications, both as monotherapy and in specific chemotherapy regimens[1][3][5][6][9].

Brand names

penpulimab-kcqx